Pfizer Inc (PFE)
Return on total capital
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings before interest and tax (EBIT) (ttm) | US$ in thousands | 11,113,000 | 6,943,000 | -1,212,000 | 1,140,000 | 3,516,000 | 12,502,000 | 24,471,000 | 33,184,000 | 35,969,000 | 34,565,000 | 33,414,000 | 28,599,000 | 24,314,000 | 17,927,000 | 13,028,000 | 9,497,000 | 7,641,000 | 8,794,000 | 16,668,000 | 17,805,000 |
| Long-term debt | US$ in thousands | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | 88,203,000 | 92,286,000 | 87,700,000 | 92,282,000 | 89,014,000 | 96,934,000 | 99,019,000 | 100,971,000 | 95,661,000 | 92,631,000 | 87,209,000 | 82,424,000 | 77,201,000 | 75,691,000 | 70,042,000 | 68,620,000 | 63,238,000 | 65,259,000 | 64,336,000 | 65,026,000 |
| Return on total capital | 12.60% | 7.52% | -1.38% | 1.24% | 3.95% | 12.90% | 24.71% | 32.86% | 37.60% | 37.31% | 38.31% | 34.70% | 31.49% | 23.68% | 18.60% | 13.84% | 12.08% | 13.48% | 25.91% | 27.38% |
December 31, 2024 calculation
Return on total capital = EBIT (ttm) ÷ (Long-term debt + Total stockholders’ equity)
= $11,113,000K ÷ ($—K + $88,203,000K)
= 12.60%
Pfizer Inc's return on total capital showed fluctuating trends over the reported periods. The ratio started strong at 27.38% in March 2020, indicating efficient utilization of both equity and debt to generate profits. However, there was a gradual decline in the ratio, reaching a low of 1.24% in March 2024, reflecting potential challenges in optimizing capital investments.
Subsequently, there was a recovery, with the ratio improving to 12.60% by December 2024. The variations in return on total capital suggest changes in Pfizer's capital structure, asset management efficiency, and profitability levels. Investors and analysts may monitor this metric closely to assess the company's ability to generate returns relative to the capital employed.
Peer comparison
Dec 31, 2024